References
- American Diabetes Association. Standards of medical care in diabetes – 2020. Diabetes Care. 2020;43(Suppl 1):S1–S212.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
- Gebel E. The start of something good: the discovery of HbA(1c) and the American Diabetes Association Samuel Rahbar outstanding discovery award. Diabetes Care. 2012;35(12):2429–2431.
- Lyon AW, Higgins T, Wesenberg JC, et al. Variation in the frequency of hemoglobin A1c (HbA1c) testing: population studies used to assess compliance with clinical practice guidelines and use of HbA1c to screen for diabetes. J Diabetes Sci Technol. 2009;3(3):411–417.
- Driskell OJ, Holland D, Hanna FW, et al. Inappropriate requesting of glycated hemoglobin (HbA1c) is widespread: assessment of prevalence, impact of national guidance, and practice-to-practice variability. Clin Chem. 2012;58(5):906–915.
- Driskell OJ, Holland D, Waldron JL, et al. Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control. Diabetes Care. 2014;37(10):2731–2737.
- Parcero AF, Yaeger T, Bienkowski RS. Frequency of monitoring hemoglobin A1C and achieving diabetes control. J Prim Care Community Health. 2011;2(3):205–208.
- Goodney PP, Newhall KA, Bekelis K, et al. Consistency of hemoglobin A1c testing and cardiovascular outcomes in medicare patients with diabetes. J Am Heart Assoc. 2016;5(8):e003566.
- Hanchak NA, Murray JF, Hirsch A, et al. USQA health profile database as a tool for health plan quality improvement. Manag Care Q. 1996;4(2):58–69.
- Glasser M, Peters K, Warner J, et al. Characteristics of diabetes patients and adherence to standards of care in rural primary care clinics. J Clin Outcomes Manag. 2010;17(8):357–361.
- Neumiller J, Sclar D, Robison L, et al. Ethnicity/race and the extent of physician-ordered hemoglobin A1c during US office-based visits by patients with diabetes mellitus. Diabetes Educ. 2010;36(1):65–66.
- Delaronde S. Barriers to A1C testing among a managed care population. Diabetes Educ. 2005;31(2):235–239.
- Pivovarov R, Albers DJ, Hripcsak G, et al. Temporal trends of hemoglobin A1c testing. J Am Med Inform Assoc. 2014;21(6):1038–1044.
- Laxmisan A, Vaughan-Sarrazin M, Cram P. Repeated hemoglobin A1C ordering in the VA health system. Am J Med. 2011;124(4):342–349.
- Kirkman MS, Williams SR, Caffrey HH, et al. Impact of a program to improve adherence to diabetes guidelines by primary care physicians. Diabetes Care. 2002;25(11):1946–1951.
- Lautsch D, Wang T, Yang L, et al. Prevalence of established cardiovascular disease in patients with type 2 diabetes mellitus in the UK. Diabetes Ther. 2019;10(6):2131–2137.
- Iglay K, Hannachi H, Howie PJ, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243–1252.
- Pantalone KM, Hobbs TM, Wells BJ, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diab Res Care. 2015;3(1):e000093.